AOD-9604
ProtocolProtocol design for AOD-9604 starts with pharmacokinetics and ends with calendar planning. The compound's ~30 min IV; longer SubQ half-life via subq/oral (capsule, lower bioavailability) administration places it in the multi-daily-dosing bucket; cycle length is 8-12 weeks with a 4-week off-period; stack integration follows route compatibility and receptor non-overlap principles.
Key Takeaways
Scheduling lens: AOD-9604's ~30 min IV; longer SubQ half-life via subq/oral (capsule, lower bioavailability) places it in the multi-daily-dosing bucket. Mechanism: Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset. Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering. Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.
Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. Schedule design for AOD-9604 starts from the pharmacokinetic constraints implied by this mechanism and the published half-life. The subsections below address daily and weekly timing, cycle length and off-period planning, stack scheduling with other compounds, and travel-and-continuity considerations.
Cycle length and off-cycle planning
Standard AOD-9604 cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.
Travel, schedule shifts, and continuity
Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any AOD-9604 protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most AOD-9604 schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.
Stack scheduling with other compounds
When AOD-9604 is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Multiple subcutaneous compounds can be combined in a single injection where compatible, or staggered through the day where pharmacokinetics differ meaningfully. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.
The most-asked scheduling question for AOD-9604 in stack scheduling is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
Schedule design for AOD-9604 in protocol calendar starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
For weekly timing scheduling, AOD-9604 is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
The most-asked scheduling question for AOD-9604 in multi-peptide timing is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 300-500 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 180-500 mcg | 4–6 weeks initial cycle |
| Protocol focus | SubQ | 300-500 mcg | 1x daily AM |
| Maintenance phase | SubQ | 210-500 mcg | Ongoing with periodic pauses |
Dose timing for AOD-9604 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
AOD-9604 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.
- AOD-9604 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with AOD-9604's mechanism in protocol / scheduling / cycling protocols.
- AOD-9604 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with AOD-9604's mechanism in protocol / scheduling / cycling protocols.
- AOD-9604 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with AOD-9604's mechanism in protocol / scheduling / cycling protocols.
- AOD-9604 + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with AOD-9604's mechanism in protocol / scheduling / cycling protocols.
No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data).
Lens-specific safety considerations for protocol / scheduling / cycling use of AOD-9604: No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data). Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| AOD-9604 | GH fragment | ~30 min IV; longer SubQ | Protocol |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
Best practice for re-cycling?
What if I miss a dose?
Daily timing for AOD-9604?
Stack timing relative to training and meals?
How do I schedule AOD-9604 alongside my existing stack?
What is the regulatory status of AOD-9604?
Start a AOD-9604 Protocol
Alukard provides physician-supervised peptide protocols with GMP-certified AOD-9604 and GMP-certified compounds with personalised cycle design.
Get ProtocolQuick Facts
- Molecular weight
- 1815.1 Da
- Sequence length
- 16 aa
- Half-life
- ~30 min IV; longer SubQ
- WADA
- Not on prohibited list (verify annually)
- FDA
- Unapproved (Research Only)
- Research
- Phase IIb completed; not commercialised
Stack Partners
All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for AOD-9604 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Protocol / Scheduling / Cycling Protocol for AOD-9604
Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.
HIPAA Compliant · GMP Certified · Physician Supervised